Dr. Donington is a Professor in Surgery and chief of the section of Thoracic Surgery. Her clinical and interests focus on the diagnosis and treatment of non-small cell lung cancer. Areas of expertise include the use of multimodality therapy for locally advanced lung cancer, treatment options for high-risk patients with early stage lung cancer and lung cancer in women. She is the surgical chair for the thoracic malignancy group of NRG Oncology Group, council member for the Western Thoracic Surgical Association, and immediate past-president of the New York Society for Thoracic Surgery, and the Women in Thoracic Surgery.
NYU
New York, NY
MS - Clinical Research
2010
Mayo Hospital and Clinics
Rochester, MN
- Cardiothoracic Surgery
2002
Georgetown University
Washington, DC
- General Surgery
1999
NIH/NCI/Surgery Branch
Bethesda, MD
- Surgical Oncology
1996
Rush University
Chicago, IL
MD - Medicine
1992
University of Michigan
Ann Arbor, MI
BS - Biology
1987
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? Ther Adv Med Oncol. 2023; 15:17588359231198446.
PMID: 37720499
Restructuring lung cancer care to accelerate diagnosis and treatment in patients vulnerable to healthcare disparities using an innovative care model.
Restructuring lung cancer care to accelerate diagnosis and treatment in patients vulnerable to healthcare disparities using an innovative care model. MethodsX. 2023 Dec; 11:102338.
PMID: 37701734
Germline Variants Incidentally Detected via Tumor-Only Genomic Profiling of Patients With Mesothelioma.
Germline Variants Incidentally Detected via Tumor-Only Genomic Profiling of Patients With Mesothelioma. JAMA Netw Open. 2023 08 01; 6(8):e2327351.
PMID: 37556141
American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma.
American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma. JAMA Oncol. 2023 07 01; 9(7):971-980.
PMID: 37186595
Treatment Decisions for Resectable Non-Small-Cell Lung Cancer: Balancing Less With More?
Treatment Decisions for Resectable Non-Small-Cell Lung Cancer: Balancing Less With More? Am Soc Clin Oncol Educ Book. 2023 May; 43:e389950.
PMID: 37220324
Current Management of Stage IIIA (N2) Non-Small-Cell Lung Cancer: Role of Perioperative Immunotherapy, and Tyrosine Kinase Inhibitors.
Current Management of Stage IIIA (N2) Non-Small-Cell Lung Cancer: Role of Perioperative Immunotherapy, and Tyrosine Kinase Inhibitors. Thorac Surg Clin. 2023 May; 33(2):189-196.
PMID: 37045488
STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer.
STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2023 01; 7:e2200273.
PMID: 36603171
Impact of Federal Lung Cancer Screening Policy on the Incidence of Early-stage Lung Cancer.
Impact of Federal Lung Cancer Screening Policy on the Incidence of Early-stage Lung Cancer. Ann Thorac Surg. 2023 04; 115(4):827-833.
PMID: 36470567
Oncologic end points and implication of trial design in the era of immunotherapy for resectable non-small cell lung cancer.
Oncologic end points and implication of trial design in the era of immunotherapy for resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 06; 165(6):1949-1953.
PMID: 36528434
Lung resection surgery in Jehovah's Witness patients: a 20-year single-center experience.
Lung resection surgery in Jehovah's Witness patients: a 20-year single-center experience. J Cardiothorac Surg. 2022 Oct 20; 17(1):272.
PMID: 36266727